We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Valirx plc (VAL) ORD GBP0.001

Sell:0.45p Buy:0.55p 0 Change: No change
Market closed |  Prices as at close on 25 April 2025 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:0.45p
Buy:0.55p
Change: No change
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 25 April 2025 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:0.45p
Buy:0.55p
Change: No change
Market closed |  Prices as at close on 25 April 2025 Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Share news, reports & tips

  • ValiRx terminates exclusive negotiations with TheoremRx

    3 April 2025 14:58

    (Sharecast News) - ValiRx announced the immediate termination of its letter of intent with TheoremRx on Thursday, ending exclusive negotiations originally set to run until 31 May.

  • ValiRx's Inaphaea inks deal with UK-based Screenin3D

    3 February 2025 12:20

    (Sharecast News) - ValiRx announced on Monday that its wholly-owned subsidiary Inaphaea BioLabs has signed an evaluation and commercial use agreement with UK-based Screenin3D.

  • ValiRx enters evaluation and option deal with Canada's Altus

    29 January 2025 11:13

    (Sharecast News) - ValiRx announced on Wednesday that it has entered into an evaluation and option agreement with Canada-based Altus Formulation to assess the potential of Altus' SmartCelle drug...

  • ValiRx further extends letter of intent with TheoremRx

    31 December 2024 11:07

    (Sharecast News) - ValiRx, a life science company specialising in early-stage cancer therapeutics and women's health, announced a further amendment to its letter of intent with TheoremRx regarding the...

  • ValiRx shares tank on £1.6m fundraising plan to support R&D

    9 December 2024 09:43

    (Sharecast News) - Shares in life sciences firm ValiRx plummeted on Monday after the AIM-listed firm announced plans to raise £1.57m to increase its R&D efforts as it continues the development of breast...

  • ValiRx subsidiary makes first sale

    18 November 2024 14:04

    (Sharecast News) - ValiRx, a life science company focussed on early-stage cancer therapeutics and women's health, announced the first sale from its wholly-owned subsidiary Inaphaea BioLabs on Monday.

  • ValiRx losses narrow in first half

    27 September 2024 11:33

    (Sharecast News) - ValiRx, a life science company focussed on cancer therapeutic development, reported a total comprehensive loss of £0.97m for the six months ended 30 June on Friday, narrowing from a...

  • ValiRx pulls out of University of Barcelona collaboration

    26 September 2024 12:05

    (Sharecast News) - ValiRx said in an update on Thursday that it has concluded its evaluation project with the University of Barcelona, focussed on early-stage cancer therapeutics targeting the...

  • ValiRx subsidiary inks agreement with research firm Xenopat

    18 September 2024 12:48

    (Sharecast News) - London-based life science company ValiRx has announced that its wholly-owned subsidiary, Inaphaea BioLabs, has entered into an evaluation and commercial use agreement with Spanish contract...

  • ValiRx inks deal with Dundee Drug Discovery Unit

    12 February 2024 12:59

    (Sharecast News) - ValiRx announced the signing of a significant agreement with the University of Dundee and its Drug Discovery Unit (DDU) on Monday.

  • ValiRx enters option deal with Ambrose Healthcare

    5 December 2023 15:08

    (Sharecast News) - Cancer therapeutics-focussed life science company ValiRx announced on Tuesday that its subsidiary ValiSeek has entered into an exclusive option agreement with Ambrose Healthcare, a private...

  • ValiRx enters partnership with StingRay Bio

    10 November 2023 10:32

    (Sharecast News) - Life science company ValiRx announced a new partnership with StingRay Bio on Friday, aiming to explore a promising lead series of drug candidates designed for oncology applications.

Company announcements Announcements


Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.

© Digital Look Ltd 1998-2025. All rights reserved.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.